# Thank you for joining. The presentation will begin shortly.

We want to better understand any barriers you are facing in providing adult immunizations.

While you wait for the webinar to start, please answer the poll.





# Rise to Immunize™ Monthly Webinar

Routine Adult Immunizations in the Age of Covid-19: Implementation Strategies for Success in an Evolving World

AMGA.

Craig W Robbins, MD, MPH, FAAFP, Kaiser Permanente





## **Campaign Updates**

- Reimbursement Form Deadline
- New Campaign Resources
- Resource: ImmYounity
- Updated Measurement Specs Reminder
- Data Sneak Peek
- Membership Poll


# Routine Adult Immunizations in the Age of Covid-19: Implementation Strategies for Success in an Evolving World


• Craig Robbins, MD, MPH, FAAFP

#### **Q&A Session**









- Will be sent via email
- Will be available on website

(RiseToImmunize.org → "Resources" → "Webinars")



Ask questions during the webinar using the **Q&A feature** 


 Questions will be answered at the end of the presentation **RIZE Action Month** 

Submit your
Reimbursement
Form and group
photo by
September 30th




# **Campaign Resources**












Visit ImmYounity.Vaccines.com

## The new pneumococcal measure is LIVE



- The <u>updated Measure Specifications document</u> with changes to the pneumococcal measure is available on the Rise to Immunize™ website.
- Please use this version (v1.3) for all future reports, beginning with the Q3 2022 report due Oct. 14<sup>th</sup>





We'll discuss trends, opportunities, and main takeaways from our first full Measurement Year, and hear from our 3 award winners.

In the meantime...

In the first year of the campaign, we have collectively administered or documented

5,078,982 vaccines

## Membership Poll

We are looking to better understand your barriers to implementation!

Please answer the 5 questions in the poll now.



# **Today's Speakers**





Craig Robbins, M.D., MPH, FAAFP

Medical Director, Care Management Institute Center for Clinical Information Services; Kaiser Permanente **PERMANENTE MEDICINE®** 

COVID-19/Influenza and Adult Immunizations: Fall 2022 Update

Presenter:

Craig W. Robbins, MD, MPH, FAAFP

TPF/CMI—Medical Director, Center for Clinical Information Services & Education

KPSOM—Associate Professor, Health Systems Science

Rise to Immunize<sup>TM</sup> Webinar

September 15, 2022



## Agenda

- Rise to Immunize/KP National Vaccination Program
- COVID & influenza: status & expectations
- New CDC vaccination recommendations:
  - COVID-19
  - Influenza
- Past Population Performance
- Improvement Strategies

## Agenda

- Rise to Immunize/KP National Vaccination Program
- COVID & influenza: status & expectations
- New CDC vaccination recommendations:
  - COVID-19
  - Influenza
- Past Population Performance
- Improvement Strategies

#### Rise to Immunize: Routine adult immunizations


- ▲ Influenza

- Zoster

15 © Permanente Medicine

#### Kaiser Permanente (KP) National Vaccination Program


- Enterprise-wide coordination of planning and resources for the administration of endemic and pandemic vaccinations.
- Ensures consistent internal and external messaging.
- Combined oversight and coordination of annual flu vaccine and primary and booster COVID-19 vaccinations.
- KP markets own and drive care delivery operations for COVID-19 and flu vaccinations.




## Agenda

- Rise to Immunize/KP National Vaccination Program
- COVID & influenza: status & expectations
- New CDC vaccination recommendations:
  - COVID-19
  - Influenza
- Past Population Performance
- Improvement Strategies

## **U.S. COVID-19 Experience: Cases**






Retrieved 9/13/2022 from: https://covid.cdc.gov/covid-data-tracker/#trends\_dailycases\_select\_00


## **U.S. COVID-19 Experience: Deaths**





Retrieved 9/13/2022 from: https://covid.cdc.gov/covid-data-tracker/#trends\_dailydeaths\_select\_00

### **U.S. COVID-19 Experience: Current Circulating Variants**



Retrieved 9/13/2022 from: https://covid.cdc.gov/covid-data-tracker/#variant-proportions

#### **Southern Hemisphere 2022 Influenza Experience**




#### INFLUENZA LABORATORY SURVEILLANCE INFORMATION Virus detections by subtype reported to FluNet



Date last refreshed (UTC)

9/13/2022 11:04:40 AM



- Non-sentinel: Data obtained from non-sentinel systems as indicated by the reporting country. Data reported in this category may include outbreak investigation, universal testing, testing at point of care or other systems apart from sentinel surveillance.
- Sentinel: Data obtained from sentinel surveillance as indicated by the reporting country. Sentinel surveillance systems collect high-quality data in a timely manner systematically and routinely from sentinel surveillance sites representatives of the population under surveillance.
- Type not defined: Source of data not indicated by the reporting country neither as sentinel nor as non-sentinel surveillance. These data may include sentinel or non-sentinel surveillance sources or both.

© Copyright World Health Organization (WHO) [2022], All Rights Reserved

Calendar type: ISO 8601

Data source: FluNet (https://www.who.int/tools/flunet)

Retrieved 9/13/2022 from: https://www.who.int/tools/flunet

## Agenda

- Rise to Immunize/KP National Vaccination Program
- COVID & influenza: status & expectations
- New CDC vaccination recommendations:
  - COVID-19
  - Influenza
- Past Population Performance
- Improvement Strategies

#### Updated CDC Guidance (9/2/2022): COVID-19 Vaccination

- ▲ COVID-19 vaccination is recommended for everyone ages 6 months and older in the United States for the prevention of COVID-19. People can stay up to date with COVID-19 vaccination by completing a primary series and receiving the most recent booster dose recommended for them by CDC.
- People ages 12 years and older are recommended to receive 1 age-appropriate bivalent mRNA booster dose after completion of any FDA-approved or FDA-authorized monovalent primary series or previously received monovalent booster dose(s). This new booster recommendation replaces all prior booster recommendations for this age group.

https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#covid-vaccines

#### **CDC Guidance: Current COVID-19 Vaccination Schedules**

#### COVID-19 Vaccination Schedule for People who are NOT Moderately or Severely Immunocompromised


#### People ages 6 months through 4 years



#### People ages 5 through 11 years



#### People ages 12 years and older



#### People ages 18 years and older who previously received Janssen primary series dose<sup>†</sup>



- \*The bivalent booster dose is administered at least 2 months after completion of the primary series. For people who previously received a monovalent booster dose(s), the bivalent booster dose is administered at least 2 months after the last monovalent booster dose.
- † Janssen COVID-19 Vaccine should only be used in certain limited situations. See: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-a

#### COVID-19 Vaccination Schedule for People who are Moderately or Severely Immunocompromised

#### People ages 6 months through 4 years



#### People ages 5 through 11 years



#### People ages 12 years and older



#### People ages 18 years and older who previously received Janssen primary series dose<sup>†</sup>



#### Monoclonal antibodies (EVUSHELD™) for COVID-19 pre-exposure prophylaxis

#### People ages 12 years and older (must weigh at least 40kg)



- \*The bivalent booster dose is administered at least 2 months after completion of the primary series. For people who previously received a monovalent booster dose(s), the bivalent booster dose is administered at least 2 months after the last monovalent booster dose.
- <sup>†</sup> Janssen COVID-19 Vaccine should only be used in certain limited situations. See: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-usappendix.html#appendix-a

https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#covid-vaccines

24 © Permanente Medicine

PERMANENTE MEDICINE®

#### CDC Guidance: Seasonal Influenza Vaccination 2022-23

- ▲ Adults aged ≥65 years are recommended to preferentially receive any one of the following higher dose or adjuvanted influenza vaccines:
  - quadrivalent high-dose inactivated influenza vaccine (HD-IIV4) \*,
  - quadrivalent recombinant influenza vaccine (RIV4) \*, or
  - quadrivalent adjuvanted inactivated influenza vaccine (aIIV4) \*\*.
- ▲ If none of these three vaccines is available at an opportunity for vaccine administration, then any other age-appropriate influenza vaccine should be used.

\*Higher dose vaccines include HD-IIV4 and RIV4, both of which contain a higher dose of HA antigen per virus than standard-dose vaccines (60 μg for HD-IIV4 and 45 μg for RIV4, compared with 15 μg for standard-dose inactivated vaccines).

\*\*Adjuvanted inactivated influenza vaccine (allV4) contains MF59 adjuvant.

https://www.cdc.gov/mmwr/volumes/71/rr/rr7101a1.htm?s\_cid=rr7101a1\_w

#### Updated CDC Guidance (9/2/2022): Vaccine Co-Administration

- ▲ COVID-19 vaccines may be administered without regard to timing of other vaccines. This includes. simultaneous administration of COVID-19 vaccine and other vaccines on the same day.
- Extensive experience with non-COVID 19 vaccines has demonstrated that **immunogenicity** and **adverse** event profiles are generally similar when vaccines are administered simultaneously as when they are administered alone.
- In accordance with general best practices, routine administration of all age-appropriate doses of vaccines simultaneously is recommended for children, adolescents, and adults for whom no specific contraindications exist at the time of the healthcare visit.


https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#covid-vaccines

## Agenda

- Rise to Immunize/KP National Vaccination Program
- COVID & influenza: status & expectations
- New CDC vaccination recommendations:
  - COVID-19
  - Influenza
- Past Population Performance
- Improvement Strategies

#### **U.S. COVID-19 Vaccination Data**





Retrieved 9/13/2022 from: <a href="https://covid.cdc.gov/covid-data-tracker/#vaccination-trends">https://covid.cdc.gov/covid-data-tracker/#vaccination-trends</a>

#### U.S. COVID-19 Vaccination Data: Primary Series Complete

Total Vaccine Doses		At Least One Dose	Fully Vaccinated First Booster Dose	Second Booster Dose	
Distributed	817,498,295	Fully Vaccinated* People	Count	Percent of US Population	
Distributed		Total	224,367,691	67.6%	
Administered	610,686,563				
1.14M  Children < 5 years of age with at least one dose since June 18, 2022  See Vaccination Demographic Trends for more information.		Population ≥ 5 Years of Age	224,000,330	71.7%	
		Population ≥ 12 Years of Age	215,055,356	75.9%	
109.0M People with a first booster dose**	23.5M People with a second booster dose***	Population ≥ 18 Years of Age	199,737,504	77.4%	
		Population ≥ 65 Years of Age	50,452,612	92.1%	
hout Those Data I View Feetnates and Download Data					

About These Data | View Footnotes and Download Data

CDC | Data as of: September 7, 2022 6:00am ET. Posted: September 8, 2022

Retrieved 9/13/2022 from: <a href="https://covid.cdc.gov/covid-data-tracker/#vaccinations\_vacc-people-additional-dose-totalpop">https://covid.cdc.gov/covid-data-tracker/#vaccinations\_vacc-people-additional-dose-totalpop</a>

29 © Permanente Medicine

#### U.S. COVID-19 Vaccination Data: First (Monovalent) Booster

Total Vaccine Doses						
Distributed	817,498,295					
Administered	610,686,563					
1.14M Children < 5 years of age with at least one dose since June 18, 2022 See Vaccination Demographic Trends for more information.						
109.0M 23.5M  People with a first booster dose**  People with a second booster dose***						

At Least One Dose	Fully Vaccinated	First Booster Dose	Second Booster Dose	
People with a First Booster Dose**		Count	Percent of Fully Vaccinated*	
Total	1	08,953,688	48.6%	
Population ≥ 5 Years of Age	1	08,951,784	48.6%	
Population ≥ 12 Years of Age	1	07,643,370	50.1%	
Population ≥ 18 Years of Age	1	03,183,221	51.7%	
Population ≥ 65 Years of Age	3	35,665,958	70.7%	

About These Data | View Footnotes and Download Data

CDC | Data as of: September 7, 2022 6:00am ET. Posted: September 8, 2022

Retrieved 9/13/2022 from: <a href="https://covid.cdc.gov/covid-data-tracker/#vaccinations\_vacc-people-additional-dose-totalpop">https://covid.cdc.gov/covid-data-tracker/#vaccinations\_vacc-people-additional-dose-totalpop</a>


### U.S. COVID-19 Vaccination Data: Second (Monovalent) Booster

Total Vaccine Doses		At Least One Dose	Fully Vaccinated	First Booster Dose	Second Booster Dose
Distributed	817,498,295	People with a Second Booster	Dose***	Count	Percent of People with a First Booster Dose
Administered	610,686,563	Population ≥ 50 Years of Age		22,176,710	34.3%
1.14M  Children < 5 years of age with at least one dose since June 18, 2022  See Vaccination Demographic Trends for more information.		Population ≥ 65 Years of Age		14,785,402	41.5%
109.0M People with a first booster dose**	23.5M People with a second booster dose***	Certain groups are <u>eligible to receive a second booster dose</u> at this time and may choose to do so based on individu benefits and risk.			choose to do so based on individual
About These Data   View F	ootnotes and Download Data		CDC	Data as of: September 7, 20	22 6:00am ET. Posted: September 8, 20


Retrieved 9/13/2022 from: https://covid.cdc.gov/covid-data-tracker/#vaccinations\_vacc-people-additional-dose-totalpop

31 © Permanente Medicine

#### Rise to Immunize Influenza Vaccination Data



#### Influenza vaccination rates over time by organization



Retrieved 9/13/2022 from: Rise to Immunize™ Blinded Comparative Report (August 31, 2022) **PERMANENTE MEDICINE**®

## Agenda

- Rise to Immunize/KP National Vaccination Program
- COVID & influenza: status & expectations
- New CDC vaccination recommendations:
  - COVID-19
  - Influenza
- Past Population Performance
- Improvement Strategies

#### Rise to Immunize: Campaign Planks



34 © Permanente Medicine

#### **KP Vaccination Implementation Strategies**

- ✓ Vaccine supply & delivery
- Strategic access points for vaccinations
  - Vaccination clinics
    - Drive-through options
  - Primary care appointments
  - Specialty care appointments
  - Inpatient opportunities
  - Urgent/Emergent care
  - Mobile health vans
- Member messaging/education
  - Sequential communication waves
  - School partnerships

- Faith partners
- Community health activities
- Prioritization of high-risk and vulnerable members
  - Age 65+ high-dose flu promotion
- ▲ Leveraging technology
  - EMR alerts
  - Vaccination dashboards
  - Special risk population reports
  - Mobile app-based geolocation reminders
- ▲ KP employee, PMG physician campaigns

#### **KP Vaccination Administration Safety Strategies**

- Staff training (vaccine standard operating procedures)
- Quality assurance checks
- Vaccine storage
- Workflow standardization
- Bar code administration
- ▲ EMR clinical decision support
  - Order sets (inpatient, ambulatory)
- ▲ EMR coding standardization
  - E.g., by manufacturer, strength, age

**PERMANENTE MEDICINE**®

## **Key Messages**

- Upcoming respiratory illness season presents a great opportunity to promote ALL vaccinations
- Co-administer COVID-19 vaccine, seasonal influenza vaccine, and other routine adult vaccines at EVERY opportunity
- ALIGN your people, processes, and technology to support increased vaccination delivery

#### **Questions?**

38 © Permanente Medicine PERMANENTE MEDICINE⊗

Craig Robbins, MD, MPH

craig.w.robbins@kp.org



# Upcoming Webinar



Topic: Reducing Flu Vaccine Disparities



Date/ Time: Thursday, October 20 at 2pm ET



Presenter: Leon Jerrells, MHA, MBA, RN, CPQH, *Kelsey-Seybold Clinic* & Laura Lee Hall, PhD, *National Minority Quality Forum* 

# **Questions?**





Submit your questions using the **Q&A feature** at the bottom of the screen